Audion Therapeutics

Audion Therapeutics and the REGAIN Consortium Announce Publication in Nature Communications of Their Phase 1/2a Trial of an Intratympanic Gamma Secretase Inhibitor for the Treatment of Mild to Moderate Sensorineural Hearing Loss

The phase 1 part of the study (Multiple Ascending Dose of 3 administrations) confirms safety and tolerability of a dose of 250 microgram of Gamma Secretase Inhibitor LY3056480 Pre-defined Primary Endpoints in the phase 2a part were not met. Post-hoc analysis of the data however showed signs of clinical efficacy in a subset of patients...
Linnaeusparkweg 10-2, 1098 EA Amsterdam, Netherlands

+31 6 46767255